intravenous adenosine is known to adversely cause facial flushing, headache, palpitations, light headedness, dizziness, blurring of vision and nausea, the local pain or discomfort and local flushing are not described. These adverse events were probably caused by intra-arterial injection of adenosine in the given case. In a clinical trial done by Costa et al,[6] adenosine injection in the brachial artery caused increased forearm blood flow by activation of the afferent fibers in the forearm producing sympathetic stimulation in addition to local vasodilator effect. Another clinical trial by Sylven et al[7] reported that, adenosine injection into the brachial artery produced ischemia like pain or discomfort in the forearm. Pain or discomfort began 12 s after administration, reached its maximum after 17 s and disappeared after 40 s. These effects were dose dependant.

Due to very short half-life the adverse effects of adenosine quickly wear off when the drug is discontinued[8]. The effects of adenosine can also be quickly interrupted using aminophylline, which acts as an antidote.

The high-risk patients for intra-arterial cannulation and drug administration are those who are morbidly obese and have a darkly pigmented skin, in a critical care setting, who are morbidly obese and have a darkly cannulation and drug administration are those which acts as an antidote.

The high-risk patients for intra-arterial injection of adenosine in the given case. In a clinical trial done by Costa et al,[6] adenosine injection in the brachial artery caused increased forearm blood flow by activation of the afferent fibers in the forearm producing sympathetic stimulation in addition to local vasodilator effect. Another clinical trial by Sylven et al[7] reported that, adenosine injection into the brachial artery produced ischemia like pain or discomfort in the forearm. Pain or discomfort began 12 s after administration, reached its maximum after 17 s and disappeared after 40 s. These effects were dose dependant.

Due to very short half-life the adverse effects of adenosine quickly wear off when the drug is discontinued[8]. The effects of adenosine can also be quickly interrupted using aminophylline, which acts as an antidote.

The high-risk patients for intra-arterial cannulation and drug administration are those who are morbidly obese and have a darkly pigmented skin, in a critical care setting, hypotensive and those with a pre-existing vascular anomaly.[2] Our case probably had an anomalous radial artery termed as anterobrachialis superficialis dorsalis radial artery which runs superficially past the radial styloid process - a site that is commonly used for cannulation of one of the terminal branches of the cephalic vein (often referred to as the intern vein).[9,10] The prevalence of this anomaly is 1%.

**Key words:** Supraventricular tachycardia; Adenosine; Intra-arterial injection

**References**

45, and relatively weak positive straining for S100. Lesions of the Carney complex were not found. Sentinel lymph node biopsy was not performed. The patient remains well with no evidence of local recurrence, lymph node metastasis or distant metastasis 2 years post-excision.

The published studies about PEM\textsuperscript{[1-2]} do not report the size of the lesion. Moreover, in the original study published by Zembowicz et al\textsuperscript{[1]} the number of children and adolescents and the size of the 41 lesions are not specified. In our case the very small size is an unusual clinical feature that could underestimate the lesion. Melanocytic tumors with indeterminate biologic or uncertain malignant potential (MelTUMP) include lesions that do not display the entire characteristic that permits a diagnosis of vertical growth phase melanoma and whose capacity to metastasize are indeterminate or uncertain.

Berk et al\textsuperscript{[2]} study considered seven cases of MelTUMP, including five lesions with spitzoid differentiation (epithelioid and spindle morphology) and two PEMs. Microscopic involvement of regional sentinel lymph nodes was present in 2/6 (33\%) of MelTUMPs.

Metastasis is compatible with PEM because, for definition, it is considered a low-grade malignant lesion, potentially capable of metastasizing. The presence of metastasis is a conclusive finding for malignancy. When a tumor is histologically defined as to have “uncertain malignant potential”, the development of metastasis shows that the diagnosis has been erroneous. When a “MelTUMP” is associated with regional lymph node metastases, Elder and Xu\textsuperscript{[3]} report the lesion as “metastatic MelTUMP” and indicate that “the biological potential of this metastatic tumour remains uncertain”. These considerations are not acceptable because the metastasis is the clinical manifestation of biological malignancy. The considerations of Berk et al. add confusion to the understanding of the MelTUMPs course in children and adolescents. PEM is distinct melanocytic entity that exhibits a low-grade malignant behavior in the form of both regional and occasional nonregional metastases, but rarely cause death. Wide local excision with clear surgical margins is recommended. Prognostic implications of sentinel lymph node positivity remain to be established. As has already been shown for the other melanocytic neoplasms, fluorescence in situ hybridization could be useful for a better assessment of the malignant/metastatic potential of PEM. Studies of large numbers of cases of PEM with long-term follow-up are necessary in order to determine the impact of individual clinico-pathological features on the biological behavior of these tumors in children and adolescents.

**Key words:** Neoplasms; Malignancy; Nevi; Melanoma

**References**

